Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,49
KB0,11
PKN9393,1-0,24
Msft2,54
IBM1,53
DCX70,3370,370,53
PFE1,45
24.2.2018 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 23.2.2018
Flexion Ther (NASDAQ Cons)
Závěr k 23.2.2018 Změna (%) Změna (USD) Objem obchodů (ks)
25,26 4,42 1,07 738 724
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 24.2.2018
Popis společnosti
Obecné informace
Název společnostiFlexion Therapeutics Inc
TickerFLXN
Kmenové akcie:Ordinary Shares
RICFLXN.O
ISINUS33938J1060
Prioritní akciePreferred Shares
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.12.2016 95
Akcie v oběhu k 31.10.2017 37 540 829
Počet akcionářů k 31.12.2016 25
MěnaUSD
Kontaktní informace
Ulice10 Mall Rd Ste 301
MěstoBURLINGTON
PSČ01803-4121
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 813 057 777
Fax13026555049

Business Summary: Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Flexion Therapeutics Inc revenues was not reported. Net loss increased 78% to $87M. Higher net loss reflects General & admn exp increase from $15M to $41.8M (expense), Interest Expense increase from $1M to $7.4M (expense), Research and development increase of 15% to $32.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.05 to -$2.73.
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 24.2.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardPatrick Mahaffy54
President, Chief Executive Officer, Co-Founder, DirectorMichael Clayman65
Chief Scientific OfficerNeil Bodick707.4.2017
Vice President, General CounselMark Levine4328.6.201728.6.2017
Vice President - SalesJohn Magee-29.9.201629.9.2016
Vice President - MarketingMark Fraga-9.3.20179.3.2017
Vice President - Market AccessDan Thornton-9.3.20179.3.2017
Chief Medical OfficerScott Kelley-11.12.20179.3.2017